Alflutop Russian longitudinal multicenter observational study: use in patients with chronic back pain (message 3)

The use of slow-acting disease-modifying symptomatic drugs, such as bioactive concentrate from small marine fish (BCSMF, Alflutop), is considered a potential element of complex therapy for chronic non-specific back pain (CNBP).

Objective: to evaluate the efficacy of the BCSMF in patients with CNBP in real-life clinical practice.

Material and methods. An open observational study included 10,047 patients with CNBP (age – 58.3±14.9 years, 58.4% women) with moderate or severe pain – 60 [50; 70] mm on the visual analogue scale (VAS). All patients received a course of BCSMF medication: 1 ml intramuscular (IM) daily No. 20 or 2 ml IM every other day No. 10. 68.8 % of patients also took non-steroidal anti-inflammatory drugs. Treatment outcomes were assessed 10 days after completion of BCSMF therapy (30 days after initiation of treatment).

Results and discussion. As a treatment result, the pain intensity according to the VAS decreased from 60 [50; 70] to 20 [10; 30] mm (p<0.0001), the patients’ overall health assessment according to the VAS increased from 50 [30; 60] to 80 [60; 90] mm (p><0.0001) and the quality of life assessment (EQ-5D) – from 0.52 [0.06; 0.66] to 0.8 [0.71; 1] points (p>< 0.0001). A good response to treatment (pain reduction >50%) was observed in 73% of patients. On average, an improvement was observed on the 8th [5; 10] day of BCSMF therapy. There were no serious adverse effects associated with the use of the drug. Older age, overweight, initially more severe pain, and the presence of comorbid conditions were slightly more frequently associated with a less pronounced response to therapy.

Conclusion. The use of BCSMF rapidly and effectively reduces the severity of pain and other symptoms associated with CNBP.

1. Parfenov VA, Yakhno NN, Davydov OS, et al. Chronic nonspecific (musculoskeletal) low back pain. Guidelines of the Russian Society for the Study of Pain (RSSP). Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2019;11(2S): 7-16. (In Russ.). doi: 10.14412/2074-2711-2019-2S-7-16

2. Karateev AE, Davydov OS, Yakhno NN, et al. Spinal osteoarthritis as a cause of chronic low back pain. Nauchno-prakticheskaya revmatologiya. 2019;57:1-16. (In Russ.).

3. Knezevic NN, Candido KD, Vlaeyen JWS, et al. Low back pain. Lancet. 2021 Jul 3; 398(10294):78-92. doi: 10.1016/S0140-6736(21)00733-9. Epub 2021 Jun 8.

4. Chen S, Chen M, Wu X, et al. Global, regional and national burden of low back pain 1990-2019: A systematic analysis of the Global Burden of Disease study 2019. J Orthop Translat. 2021 Sep 10;32:49-58. doi: 10.1016/j.jot.2021.07.005.

5. Orrillo E, Vidal Neira L, Piedimonte F, et al. What Is New in the Clinical Management of Low Back Pain: A Narrative Review. Cureus. 2022 Mar 9;14(3):e22992. doi: 10.7759/cureus.22992. eCollection 2022 Mar.

6. Lee SW, Nguyen D, Mack D, et al. Conservative Management of Low Back Pain. HCA Healthc J Med. 2021 Oct 29;2(5):319-328. doi: 10.36518/2689-0216.1261.

7. Cashin AG, Wand BM, O'Connell NE, et al. Pharmacological treatments for low back pain in adults: an overview of Cochrane Reviews. Cochrane Database Syst Rev. 2023 Apr 4;4(4):CD013815. doi: 10.1002/14651858. CD013815.pub2.

8. Lila AM, Alekseeva LI, Taskina EA, Kashevarova NG. Osteoarthritis as an interdisciplinary problem: treatment algorithm for physicians and general practitioners. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2021;15(5):68-75. (In Russ.). doi:10.14412/1996-7012-2021-5-68-75

9. Gellhorn AC, Katz JN, Suri P. Osteoarthritis of the spine: the facet joints. Nat Rev Rheumatol. 2013 Apr;9(4):216-24. doi: 10.1038/nrrheum.2012.199. Epub 2012 Nov 13.

10. Manchikanti L, Boswell MV, Singh V, et al. Prevalence of facet joint pain in chronic spinal pain of cervical, thoracic, and lumbar regions. BMC Musculoskelet Disord. 2004 May 28;5:15. doi: 10.1186/1471-2474-5-15.

11. Rustenburg CME, Emanuel KS, Peeters M, et al. Osteoarthritis and intervertebral disc degeneration: Quite different, quite similar. JOR Spine. 2018 Oct 19;1(4):e1033. doi: 10.1002/jsp2.1033. eCollection 2018 Dec.

12. Karateev AE. Chronic back pain as a spinal osteoarthritis manifestation: rationale and practice of symptomatic slow acting drugs for osteoarthritis use. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2022; 16(4):88-97. (In Russ.). doi: 10.14412/1996-7012-2022-4-88-97

13. Lila AM, Alekseeva LI, Taskina EA, Kashevarova NG. Alflutop Russian longitudinal multicentre observational study: preliminary results (message 1). Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2023; 17(2):57-64. (In Russ.). doi: 10.14412/1996-7012-2023-2-57-64

14. Lila AM, Taskina EA, Alekseeva LI, Kashevarova NG. Multicenter Longitudinal Observational Study Pharmaceuticals Alflutop in Russia (message 2). Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2023; 17(4):75-85. (In Russ.). doi: 10.14412/1996-7012-2023-4-75-85

15. Olariu L, Dimitriu B, Manuela Ene D, et al. In vitro effect of Alflutop on the mechanisms of osteoarthritis development. Vestnik Akademii rumynskikh uchenykh. 2017;(6)1:82-99. (In Russ.).

16. Levin OS, Olyunin DYu, Golubeva LV. Efficacy of alflutop in chronic vertebrogenic lumboishialgia according to a double-blind placebo-controlled study. Nauchno-prakticheskaya revmatologiya. 2004;(4):80-3. (In Russ.).